slides · global inventory
Table Data
Tool collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 16,285
Current window 8,701-8,730
Pages 543
Rows per page 30
Tool
8,701-8,730 of 16,285
23
Includes logos of strategic shareholders: Qatar Airways, SGX, FedEx, IAG Cargo, and LATAM.Freightos | Investor Presentation Deck | 33 slides · Freightos
Pitch deck Investor relations 1 hit
27
Includes a footnote regarding non-recurring share-based listing expenses.Freightos | Investor Presentation Deck | 33 slides · Freightos
Pitch deck Investor relations 1 hit
28
The table includes non-GAAP financial measures (Adjusted EBITDA) and adjustments for non-recurring items.Freightos | Investor Presentation Deck | 33 slides · Freightos
Pitch deck Investor relations 1 hit
29
The table includes adjustments for share-based compensation and depreciation & amortization to arrive at non-IFRS metrics.Freightos | Investor Presentation Deck | 33 slides · Freightos
Pitch deck Investor relations 1 hit
30
The table shows a consistent increase in revenue alongside rising operating expenses and operating losses.Freightos | Investor Presentation Deck | 33 slides · Freightos
Pitch deck Investor relations 1 hit
31
The table reconciles IFRS gross profit to Non-IFRS gross profit by adding back share-based compensation and depreciation & amortization.Freightos | Investor Presentation Deck | 33 slides · Freightos
Pitch deck Investor relations 1 hit
11
The slide uses a table to categorize recent expansions into acquisitions and greenfield openings.GMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations Beat · Financials1 hit
18
Includes operational metrics like business days and branch counts.GMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations 1 hit
19
Includes supplemental cash flow disclosures and a non-GAAP reconciliation for free cash flow.GMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations 1 hit
20
The table breaks down net sales by organic growth, acquisitions, and FX impact, as well as by product category (Wallboard, Ceilings, Steel Framing, Complementary Products).GMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations 1 hit
21
Includes a commentary section explaining specific adjustment line items.GMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations 1 hit
22
The table includes a detailed breakdown of adjustments including stock appreciation rights, equity-based compensation, and acquisition-related costs.GMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations 1 hit
23
Includes footnotes A and B explaining specific adjustments.GMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations 1 hit
24
The table includes a commentary section explaining the specific adjustments (A-E).GMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations 1 hit
25
Includes footnotes detailing adjustments for unamortized discounts and deferred financing costs.GMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations 1 hit
26
GMS | Investor Conference Presentation Deck | 26 slidesGMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations 1 hit
20
The table uses a standard pharmaceutical pipeline format, categorizing by clinical vs preclinical status and highlighting specific regulatory and clinical trial milestones.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
24
The slide uses a red dashed box to highlight the primary efficacy metrics (response rates).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
26
The slide uses a comparison table framework to highlight competitive advantage in clinical metrics.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
29
The table displays clinical trial data for NXC-201, specifically focusing on Cytokine Release Syndrome (CRS) and Immune cell associated Neurotoxicity (ICANS).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
30
The slide highlights specific safety metrics (CRS and ICANS) for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
31
Includes FDA approval precedents in the footer.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
56
Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
14
Kering | Investor Presentation Deck | 55 slidesKering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Rising Success1 hit
19
Includes commentary on EBIT margin dilution and CAPEX phasing.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · The BreakthroughLoop · Maturity Curve1 hit
46
Includes two donut charts representing store counts and revenue share, and a table detailing quarterly performance by geography.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
47
Includes two donut charts showing store count and revenue breakdown, plus a table of quarterly performance metrics.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
48
Includes H1 2023 revenue of €833m, store count of 279, and regional revenue splits alongside quarterly YoY comparable growth rates.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
49
Kering | Investor Presentation Deck | 55 slidesKering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
50
Kering | Investor Presentation Deck | 55 slidesKering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit